Markets

Lexicon (LXRX) Jumps: Stock Moves 7.6% Higher - Tale of the Tape

A generic image of two people across from each other
Credit: Shutterstock photo

Lexicon Pharmaceuticals, Inc. ( LXRX ) was a big mover last session with its shares rising nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend of the company as the stock has lost almost 4% in the past one-month time frame.

This biotechnology company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn't been in trend either. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Lexicon currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Investors interested in the biomedical industry may also consider stocks like Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and Osiris Therapeutics, Inc. ( OSIR ). All the three stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

LEXICON PHARMA (LXRX): Free Stock Analysis Report

ACTELION LTD (ALIOF): Get Free Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

OSIRIS THERAPTC (OSIR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BIIB LXRX

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More